|1.||Saniabadi, Abby R: 2 articles (06/2007 - 09/2002)|
|2.||Asao, Takayuki: 2 articles (06/2007 - 09/2002)|
|3.||Yazawa, Shin: 2 articles (06/2007 - 09/2002)|
|4.||Ide, Munenori: 2 articles (06/2007 - 09/2002)|
|5.||Noguchi, Kasumi: 1 article (06/2007)|
|6.||Kominato, Yoshihiko: 1 article (06/2007)|
|7.||Kuwano, Hiroyuki: 1 article (06/2007)|
|8.||Tsuboi, Kaori: 1 article (06/2007)|
|9.||Hashimoto, Shinji: 1 article (06/2007)|
|10.||Kochibe, Naohisa: 1 article (09/2002)|
|1.||Hypertension (High Blood Pressure)
06/01/1987 - "In 20 patients with mild or moderate essential hypertension who responded favorably to indenolol antihypertensive therapy, echocardiography was performed in the basal condition and 6 and 12 months after the beginning of permanent antihypertensive treatment. "
03/01/1987 - "The antihypertensive effects of indenolol, a new not-cardioselective beta-blocking agent, were evaluated in patients with WHO grades I and II essential hypertension (range 160/95 to 200/115 mm Hg) in a double-blind, placebo-controlled study after acute (12 patients) and 2-week treatment (seven patients). "
12/01/1986 - "The aim of this study was to evaluate BAR density and affinity before and after indenolol therapy in membranes of polymorphonucleates (PMN) of patients with essential hypertension. "
11/01/1990 - "[Effects of indenolol on left ventricular mass in patients with essential arterial hypertension]."
09/01/1986 - "Indenolol kinetics versus pharmacodynamics in hypertension."
11/01/1990 - "This study evaluated the effect of long-term antihypertensive therapy with indenolol, a beta blocking agent with beta 2 stimulating activity, its antihypertensive hemodynamic mechanism and its effect on hypertensive left ventricular (LV) hypertrophy. "
11/01/1990 - "Indenolol caused a regression of LV hypertensive hypertrophy without impairment of LV systolic function."
|3.||Colorectal Neoplasms (Colorectal Cancer)
06/01/1993 - "Therefore, YB-2 antibody could be useful as an immunochemical tool for diagnosis and evaluation of the prognosis of colorectal cancer."
06/01/2007 - "By using the YB-2 monoclonal antibody, the resulting products have been identified as Y, Le(b), and H type 2 antigens in colorectal tumor tissues. "
09/01/2002 - "The accumulation of alpha1,2fucosylated antigens, such as Y (Fucalpha1,2Galbeta1,4 [Fucalpha1,3]GlcNAcbeta), Le(b) (Fucalpha1,2Galbeta1,3-[Fucalpha1,4]GlcNAcbeta), and H type 2 (Fucalpha1,2 Galbeta1,4GlcNAcbeta) occurs specifically within human colorectal tumor tissues and can be detected by an antifucosylated antigen antibody, such as the YB-2 antibody. "
06/01/1993 - "The expression of fucosylated antigens detected by YB-2 antibody seemed to be correlated with survival among patients with primary colorectal cancer. "
06/01/1993 - "Development and characterization of a novel anti-fucosylated antigen monoclonal antibody YB-2 and its usefulness in the immunohistochemical diagnosis of colorectal cancer."
04/01/1981 - "Dose-response curves for both drugs revealed that maximum attenuation of exercise tachycardia and systolic blood pressure were in the same range but suggested that indenolol induced a greater response in the lower doses. "
04/01/1981 - "Indenolol induced attenuation of exercise-induced rise in systolic blood pressure and tachycardia. "
02/01/1986 - "In conscious SHRs the acute hypotensive effect of oral indenolol and pindolol was associated with marked bradycardia and moderate tachycardia respectively, while the decrease in heart rate following propranolol was concomitant to a slight increase in blood pressure. "
|5.||Body Weight (Weight, Body)
01/01/1988 - "The blood levels of indenolol were determined in rats following nasal and intravenous administration of 5 mg/kg body weight of the drug. "
09/01/1984 - "Albino rats were administered with lg/kg body weight of sucralfate just before the oral administration of indenolol solution (10 mg/kg), blood samples were collected at 0,15,30,45,60,120,240 and 360 minutes after the administration of drugs. "
|7.||beta Adrenergic Receptors
|8.||Pindolol (LB 46)